NEW YORK (
) -- Shares of specialty pharma company
were zooming over 150% to $3.85 after U.S. regulators approved its drug, Makena, used to reduce the risk of preterm birth in women with a history of going into labor earlier than 37 weeks. Over 11 million shares were changing hands in afternoon trading.
Shares of timeshare operator
soared 70% to $2.44 after hedge fund
said it would buy the company for $94 million, a 75% premium to its previous day's closing price.
saw its share spurt 30% to $2.62 after it said its losses narrowed in the fiscal third quarter and issued an upbeat forecast for the fourth quarter.
(OREX - Get Report)
were once again attracting buying interest. The stock crashed over 70% earlier this week after regulators rejected its obesity drug. But shares were climbing 17% on Friday to $3.46.
denied a short-seller's allegations of fraud late Thursday. Muddy Waters Research, which has a short position in the stock, had accused the company of
engaging in a massive pump and dump scheme.
Shares were surging Friday by nearly 20% to $13.50 after plunging by 33% on Thursday.
jumped 15% to $8.87 after its results and first quarter forecasts beat estimates.
and video services provider
were also prominent gainers in the small-cap sector on Friday trading.
-- Written by Shanthi Bharatwaj in New York
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to: